Pre-Conference: The Promise and Pitfalls of Real-world evidence in Alzheimer’s Disease

Pre-Conference: The Promise and Pitfalls of Real-world evidence in Alzheimer’s Disease

THE PROMISE AND PITFALLS OF REAL-WORLD EVIDENCE IN ALZHEIMER'S DISEASE

Pre-Conference Full Day Satellite Symposium
Tuesday, March 26, 2019
08:30 -17:00

Pre-Registration is required. To register, please click here

Session 1
Title: Perspectives on Real-World Evidence and Alzheimer's Disease
Chair: Lutz Froelich, germany

08:30 -Welcome Address
Lutz Froelich, Germany

08:40 - A Primer on Real-World Evidence (RWE)
Magali Haas, USA

09:10 -RWE needs: A US perspective
Marwan Sabbagh, USA

09:30 - RWE needs: A EU perspective
Pieter Jeller Visser, The Netherlands

09:50 - RWE needs: An Australian perspective
Colin Masters, Australia

10:10 - Q&A

10:30 -Coffee Break

Session 2
Title: Key RWE initiatives in AD: What did we learn to date?
Chairs: Colin Masters

11:00 - ADNI
Mike Weiner, USA

11:20 - ROADMAP

Sarah Bauermeister, United Kingdom

11:40 - EPAD and AMYPAD
Jose Luis Molinuevo, Spain

12:00 -REAL-WORLD OUTCOMES FOR ALZHEIMER’S DISEASE
Chris Edgar, United Kingdom

12:20 - Panel Discussion

12:45 -Lunch Break

Session 3 Biomarkers: The magic bullet in RWE?
Time: 14:00-15:30
Chairs: Jose Luis Molineuvo, Spain

14:00 - Fluid Biomarkers
Henrik Zetterberg, Sweden

14:20 - Imaging Biomarkers
Christopher Rowe, Australia

14:40 - Digital Biomarkers
Hiroko Dodge, USA

15:00 -Panel Discussion

15:30 - Coffee Break

Session 4
Title: The Path Forward addressing stakeholder expectations
Chairs: lutz froelich, germany

15:45 - Stakeholders’ needs, wants, and expectations 

Patient Perspective: Jean Georges, Belgium

Regulatory Perspective:Cristina Sampaio, USA
Payor Perspective:Katy Harrison, UK

16:30 - Bringing it all together
Lutz Froelich, Germany